AK-139

N/A

Report date: 2026/04/07 20:00:20

Base Information

Drug NameAK-139
Drug Alias NameAK139AK-139
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Interleukin-4 receptor subunit alphaInterleukin-1 receptor-like 1 modulators
TargetsInterleukin-4 receptor subunit alphaInterleukin-1 receptor-like 1
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Prurigo NodularisHypersensitivity +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesKangfang Biotechnology (Cayman) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAkeso Pharmaceuticals IncKangfang Biotechnology (Cayman) Co LtdZhongshan Akeso Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Prurigo NodularisHypersensitivity +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A